ArticleFrontiers in immunology2025
Long-term outcomes of aortic valve insufficiency in patients with Takayasu arteritis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Contemporary Overview of Aortic Regurgitation in Young Individuals: Insights From Real-Life Evidence.Journal of the American Heart Association · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Takayasu arteritis (TAK) is a rare vasculitis predominantly affecting the aorta and its branches. Aortic valve (AV) insufficiency is a clinically significant but underexplored manifestation of TAK. This study aimed to evaluate the prevalence, associated risk factors, and prognostic implications of AV insufficiency in a large, multicenter cohort of TAK patients. Methods: We retrospectively analyzed data from 252 patients diagnosed with TAK across 11 rheumatology centers in Türkiye. Echocardiographic findings, clinical characteristics, treatment data, and long-term outcomes were collected. Severity and progression of AV insufficiency were assessed using standardized echocardiographic criteria. Results: AV insufficiency was present in 33% of patients, with moderate to severe forms observed in 12% and with 7% requiring valve replacement. Ascending aorta and renal artery involvement, hypertension, and heart failure were more frequent in patients with AV insufficiency. Over a median follow-up of 97 months, AV insufficiency progressed in 17% of baseline affected patients. The absence of subclavian artery involvement and vascular damage index (VDI) were found to be independent risk factors for AV insufficiency progression. Despite the structural progression, AV insufficiency did not significantly impact mortality, relapse rates, vascular damage index, or treatment patterns. Conclusion: AV insufficiency is the most clinically relevant valvular pathology in TAK, and its baseline presence did not adversely influence TAK disease outcomes. Progression was observed in a subset of patients, and this was associated with higher VDI scores, particularly among those without subclavian artery involvement. Timely diagnosis and multidisciplinary management may mitigate its impact on long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.